期刊
EUROPEAN JOURNAL OF NEUROSCIENCE
卷 56, 期 9, 页码 5532-5546出版社
WILEY
DOI: 10.1111/ejn.15591
关键词
Alzheimer's disease; amyloid; EphA-4; ephrins; neurodegeneration; neurofibrillary tangles
EphA-4 plays a significant role in the onset and progression of Alzheimer's disease. Inhibition of EphA-4 can alleviate symptoms and affect the development of the disease. Further research on the regulation pathways of EphA-4 and the development of therapeutic methods targeting its enzymatic activity are important.
Erythropoietin-producing hepatoma (Eph) receptors belong to a family of tyrosine kinase receptors that plays a pivotal role in the development of the brain. Eph can be divided broadly into two groups, namely, EphA and EphB, comprising nine and five members, respectively. In recent years, the role of EphA-4 has become increasingly apparent in the onset of Alzheimer's disease (AD). Emerging evidence suggests that EphA-4 results in synaptic dysfunction, which in turn promotes the progression of AD. Moreover, pharmacological or genetic ablation of EphA-4 in the murine model of AD can alleviate the symptoms. The current review summarizes different pathways by which EphA-4 can influence pathogenesis. Since, majority of the studies had reported the protective effect of EphA-4 inhibition during AD, designing therapeutics based on decreasing its enzymatic activity might be necessary for introducing the novel interventions. Therefore, the review described peptide and nanobodies inhibitors of EphA-4 that exhibit the potential to modulate EphA-4 and could be used as lead molecules for the targeted therapy of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据